

# Eradication of *Helicobacter pylori* and recurrence of bleeding peptic ulcers

<b>Submission date</b> 10/10/2002	<b>Recruitment status</b> Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 10/10/2002	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 22/10/2010	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr J J Y Sung

**Contact details**  
Department of Medicine & Therapeutics  
Prince of Wales Hospital  
30 Ngan Shing Street  
Sha Tin  
Hong Kong  
-

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

**Secondary identifying numbers**  
511003

## Study information

## **Scientific Title**

### **Study objectives**

Not provided at time of registration

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Not provided at time of registration

### **Study design**

Randomised controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Treatment

## **Participant information sheet**

### **Health condition(s) or problem(s) studied**

Recurrence of bleeding peptic ulcers

### **Interventions**

Added as of 09/11/2009: Please note that this trial did not start as similar studies were carried out by other research groups.

Interventions:

Patients were randomised to receive:

1. Either a one week course of triple therapy with bismuth subcitrate, metronidazole, and tetracycline plus ranitidine, or
2. A six week course of ranitidine 300 mg/day.

After the ulcers healed, the antibiotic-treated patients were not given any medication whereas the ranitidine-treated patients continued to receive a maintenance dose of ranitidine 150 mg /day.

### **Intervention Type**

Drug

## **Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Bismuth subcitrate, metronidazole, tetracycline, ranitidine

**Primary outcome measure**

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/10/2002

**Completion date**

01/10/2003

**Reason abandoned (if study stopped)**

Objectives no longer viable

## **Eligibility**

**Key inclusion criteria**

1. Patients over the age of 16
2. Confirmed bleeding from either Duodenal (DU) or Gastric (GU) ulcers with or without stigmata of recent haemorrhage
3. A positive rapid urease test

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/10/2002

**Date of final enrolment**

01/10/2003

# Locations

## Countries of recruitment

Hong Kong

United Kingdom

## Study participating centre

Department of Medicine & Therapeutics

Sha Tin

Hong Kong

-

# Sponsor information

## Organisation

Hong Kong Health Services Research Fund (Hong Kong)

## Sponsor details

Health Welfare and Food Bureau

Government Secretariat, HKSAR

20th floor Murray Building

Garden Road

-

Hong Kong

-

+852 2973 8288

hsrf@hwfb.gov.hk

## Sponsor type

Research organisation

## ROR

<https://ror.org/03qh32912>

# Funder(s)

## Funder type

Research organisation

## Funder Name

Hong Kong Health Services Research Fund (Hong Kong)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration